Sunil Krishnan1, Awalpreet S Chadha2, Yelin Suh3, Hsiang-Chun Chen4, Arvind Rao5, Prajnan Das2, Bruce D Minsky2, Usama Mahmood2, Marc E Delclos2, Gabriel O Sawakuchi6, Sam Beddar3, Matthew H Katz7, Jason B Fleming7, Milind M Javle8, Gauri R Varadhachary8, Robert A Wolff8, Christopher H Crane2. 1. Department of Radiation Oncology, The University of Texas, Houston, Texas. Electronic address: skrishnan@mdanderson.org. 2. Department of Radiation Oncology, The University of Texas, Houston, Texas. 3. Department of Radiation Physics, The University of Texas, Houston, Texas. 4. Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas. 5. Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, Texas. 6. Department of Radiation Physics, The University of Texas, Houston, Texas; Graduate School of Biomedical Sciences, The University of Texas, Houston, Texas. 7. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
PURPOSE: To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with curative intent. METHODS AND MATERIALS: A total of 200 patients with LAPC were treated with induction chemotherapy followed by chemoradiation between 2006 and 2014. Of these, 47 (24%) having tumors >1 cm from the luminal organs were selected for dose-escalated IMRT (biologically effective dose [BED] >70 Gy) using a simultaneous integrated boost technique, inspiration breath hold, and computed tomographic image guidance. Fractionation was optimized for coverage of gross tumor and luminal organ sparing. A 2- to 5-mm margin around the gross tumor volume was treated using a simultaneous integrated boost with a microscopic dose. Overall survival (OS), recurrence-free survival (RFS), local-regional and distant RFS, and time to local-regional and distant recurrence, calculated from start of chemoradiation, were the outcomes of interest. RESULTS: Median radiation dose was 50.4 Gy (BED = 59.47 Gy) with a concurrent capecitabine-based (86%) regimen. Patients who received BED >70 Gy had a superior OS (17.8 vs 15.0 months, P=.03), which was preserved throughout the follow-up period, with estimated OS rates at 2 years of 36% versus 19% and at 3 years of 31% versus 9% along with improved local-regional RFS (10.2 vs 6.2 months, P=.05) as compared with those receiving BED ≤70 Gy. Degree of gross tumor volume coverage did not seem to affect outcomes. No additional toxicity was observed in the high-dose group. Higher dose (BED) was the only predictor of improved OS on multivariate analysis. CONCLUSION: Radiation dose escalation during consolidative chemoradiation therapy after induction chemotherapy for LAPC patients improves OS and local-regional RFS.
PURPOSE: To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with curative intent. METHODS AND MATERIALS: A total of 200 patients with LAPC were treated with induction chemotherapy followed by chemoradiation between 2006 and 2014. Of these, 47 (24%) having tumors >1 cm from the luminal organs were selected for dose-escalated IMRT (biologically effective dose [BED] >70 Gy) using a simultaneous integrated boost technique, inspiration breath hold, and computed tomographic image guidance. Fractionation was optimized for coverage of gross tumor and luminal organ sparing. A 2- to 5-mm margin around the gross tumor volume was treated using a simultaneous integrated boost with a microscopic dose. Overall survival (OS), recurrence-free survival (RFS), local-regional and distant RFS, and time to local-regional and distant recurrence, calculated from start of chemoradiation, were the outcomes of interest. RESULTS: Median radiation dose was 50.4 Gy (BED = 59.47 Gy) with a concurrent capecitabine-based (86%) regimen. Patients who received BED >70 Gy had a superior OS (17.8 vs 15.0 months, P=.03), which was preserved throughout the follow-up period, with estimated OS rates at 2 years of 36% versus 19% and at 3 years of 31% versus 9% along with improved local-regional RFS (10.2 vs 6.2 months, P=.05) as compared with those receiving BED ≤70 Gy. Degree of gross tumor volume coverage did not seem to affect outcomes. No additional toxicity was observed in the high-dose group. Higher dose (BED) was the only predictor of improved OS on multivariate analysis. CONCLUSION: Radiation dose escalation during consolidative chemoradiation therapy after induction chemotherapy for LAPCpatients improves OS and local-regional RFS.
Authors: Christopher G Willett; Carlos Fernandez Del Castillo; Helen A Shih; Saveli Goldberg; Peter Biggs; Jeffrey W Clark; Gregory Lauwers; David P Ryan; Andrew X Zhu; Andrew L Warshaw Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: C J McGinn; M M Zalupski; I Shureiqi; J M Robertson; F E Eckhauser; D C Smith; D Brown; G Hejna; M Strawderman; D Normolle; T S Lawrence Journal: J Clin Oncol Date: 2001-11-15 Impact factor: 44.544
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: C G Moertel; S Frytak; R G Hahn; M J O'Connell; R J Reitemeier; J Rubin; A J Schutt; L H Weiland; D S Childs; M A Holbrook; P T Lavin; E Livstone; H Spiro; A Knowlton; M Kalser; J Barkin; H Lessner; R Mann-Kaplan; K Ramming; H O Douglas; P Thomas; H Nave; J Bateman; J Lokich; J Brooks; J Chaffey; J M Corson; N Zamcheck; J W Novak Journal: Cancer Date: 1981-10-15 Impact factor: 6.860
Authors: B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne Journal: Ann Oncol Date: 2008-05-07 Impact factor: 32.976
Authors: Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar Journal: Int J Radiat Oncol Biol Phys Date: 2013-04-05 Impact factor: 7.038
Authors: Somnath Mukherjee; Christopher N Hurt; John Bridgewater; Stephen Falk; Sebastian Cummins; Harpreet Wasan; Tom Crosby; Catherine Jephcott; Rajarshi Roy; Ganesh Radhakrishna; Alec McDonald; Ruby Ray; George Joseph; John Staffurth; Ross A Abrams; Gareth Griffiths; Tim Maughan Journal: Lancet Oncol Date: 2013-03-06 Impact factor: 41.316
Authors: Awalpreet S Chadha; Jillian R Gunther; Cheng-En Hsieh; Maureen Aliru; Lakshmi S Mahadevan; Bhanu P Venkatesulu; Christopher H Crane; Prajnan Das; Joseph M Herman; Eugene J Koay; Cullen Taniguchi; Emma B Holliday; Bruce D Minsky; Yelin Suh; Peter Park; Gabriel Sawakuchi; Sam Beddar; Bruno C Odisio; Sanjay Gupta; Evelyne Loyer; Harmeet Kaur; Kanwal Raghav; Milind M Javle; Ahmed O Kaseb; Sunil Krishnan Journal: Radiother Oncol Date: 2019-01-16 Impact factor: 6.280
Authors: Avani D Rao; Ziwei Feng; Eun Ji Shin; Jin He; Kevin M Waters; Stephanie Coquia; Robert DeJong; Lauren M Rosati; Lin Su; Dengwang Li; Juan Jackson; Stephen Clark; Jeffrey Schultz; Danielle Hutchings; Seong-Hun Kim; Ralph H Hruban; Theodore L DeWeese; John Wong; Amol Narang; Joseph M Herman; Kai Ding Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-14 Impact factor: 7.038
Authors: Pankaj K Singh; Amit A Deorukhkar; Bhanu P Venkatesulu; Xiaolin Li; Ramesh Tailor; John S Bomalaski; Sunil Krishnan Journal: Mol Cancer Ther Date: 2019-08-08 Impact factor: 6.261
Authors: Ziwei Feng; Avani D Rao; Zhi Cheng; Eun Ji Shin; Joseph Moore; Lin Su; Seong-Hun Kim; John Wong; Amol Narang; Joseph M Herman; Todd McNutt; Dengwang Li; Kai Ding Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-19 Impact factor: 7.038
Authors: Avani Dholakia Rao; Eun Ji Shin; Jeffrey Meyer; Elizabeth L Thompson; Wei Fu; Chen Hu; Elliot K Fishman; Matthew Weiss; Christopher Wolfgang; Richard Burkhart; Jin He; Tossapol Kerdsirichairat; Joseph M Herman; Kai Ding; Amol Narang Journal: Pract Radiat Oncol Date: 2020-03-07